Goldfrank Deborah, Chuai Shannon, Bernstein Jonine L, Ramon Y Cajal Teresa, Lee Johanna B, Alonso M Carmen, Diez Orland, Baiget Monserrat, Kauff Noah D, Offit Kenneth, Robson Mark
Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2311-3. doi: 10.1158/1055-9965.EPI-06-0176.
Women who carry mutations in either the BRCA1 or BRCA2 genes are at risk for early-onset breast cancer and are recommended to begin screening mammography at age 25 to 30 years. Results of in vitro and animal studies suggest that BRCA1/BRCA2 mutation carriers are hypersensitive to ionizing radiation and possibly to radiation-induced breast cancer. This study was undertaken to investigate the association of low-dose radiation exposure from mammograms with breast cancer status in BRCA mutation carriers. One hundred sixty-two female mutation carriers provided information at time of genetic testing about exposure to mammograms before enrollment. Using unconditional logistic regression, breast cancer status was not associated with number of mammograms received before diagnosis (affected women) or ascertainment [unaffected women; adjusted odds ratio (OR), 0.94; P = not significant]. A larger group of 213 women provided information about lifetime number of mammograms. There was no association between mammogram exposure and risk in the group as a whole (adjusted OR, 1.04; P = not significant), although there was a modest association in BRCA1 carriers (adjusted OR, 1.08; P = 0.03). These findings indicate that screening mammography is unlikely to be associated with a large increase in breast cancer risk in this population.
携带BRCA1或BRCA2基因变异的女性有患早发性乳腺癌的风险,建议在25至30岁开始进行乳腺钼靶筛查。体外和动物研究结果表明,BRCA1/BRCA2基因变异携带者对电离辐射高度敏感,可能对辐射诱发的乳腺癌也敏感。本研究旨在调查乳腺钼靶低剂量辐射暴露与BRCA基因变异携带者乳腺癌状态之间的关联。162名女性基因变异携带者在基因检测时提供了入组前乳腺钼靶检查暴露情况的信息。采用非条件逻辑回归分析,乳腺癌状态与诊断前(患病女性)或确诊时(未患病女性)接受乳腺钼靶检查的次数无关[校正比值比(OR),0.94;P值无统计学意义]。另一组213名女性提供了终生乳腺钼靶检查次数的信息。总体而言,乳腺钼靶检查暴露与风险之间无关联(校正OR,1.04;P值无统计学意义),尽管在BRCA1基因变异携带者中有适度关联(校正OR,1.08;P = 0.03)。这些发现表明,乳腺钼靶筛查不太可能使该人群的乳腺癌风险大幅增加。